Volume 11 Supplement 3
Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size
© Fischer Walker and Black; licensee BioMed Central Ltd. 2011
Published: 13 April 2011
Diarrhea mortality remains a leading cause of child death and rotavirus vaccine an effective tool for preventing severe rotavirus diarrhea. New data suggest vaccine efficacy may vary by region.
We reviewed published vaccine efficacy trials to estimate a regional-specific effect of vaccine efficacy on severe rotavirus diarrhea and hospitalizations. We assessed the quality of evidence using a standard protocol and conducted meta-analyses where more than 1 data point was available.
Rotavirus vaccine prevented severe rotavirus episodes in all regions; 81% of episodes in Latin America, 42.7% of episodes in high-mortality Asia, 50% of episodes in sub-Saharan Africa, 88% of episodes low-mortality Asia and North Africa, and 91% of episodes in developed countries. The effect sizes observed for preventing severe rotavirus diarrhea will be used in LiST as the effect size for rotavirus vaccine on rotavirus-specific diarrhea mortality.
Vaccine trials have not measured the effect of vaccine on diarrhea mortality. The overall quality of the evidence and consistency observed across studies suggests that estimating mortality based on a severe morbidity reduction is highly plausible.
Diarrhea remains the second leading cause of death around the world for children under 5 years of age . Because the majority of diarrhea deaths occur in the low and middle-income countries, the etiologic agents responsible for diarrhea deaths among young children are unknown. Using hospitalization data as a best estimate of severe diarrheal disease and a proxy for diarrhea mortality, it has been estimated that rotavirus may be responsible for up to 39% of child deaths, the majority of which occur in low and middle income countries .
Several rotavirus vaccines have been introduced in the US market since the late 1990s. The current vaccines include a monovalent attenuated human rotavirus vaccine and a pentavalent human-bovine reassortant vaccine. Previous reviews, including a Cochrane review and a systematic review recently published by our group have quantified the pooled efficacy of these vaccines on severe diarrheal disease as well as diarrhea mortality among children in developed countries and a selected group of Latin American middle-income countries [3, 4]. Until recently, data from trials in sub-Saharan Africa and Asia had not been published and thus not yet included in meta-analyses of published effect sizes [5–8].
With the publication of the final results from trials in sub-Saharan Africa and Asia, it is critical to re-evaluate the evidence to date. The Lives Saved Tool (LiST) uses vaccine efficacy to model the total lives that could be saved with introduction and scale up of rotavirus vaccine in low- and middle-income countries. Because new data suggest substantial variation in vaccine efficacy by region, we estimate regional-specific vaccine efficacy on rotavirus mortality to be used in program planning by incorporation into LiST.
We previously conducted and published the results of a systematic review to identify studies assessing the effect of rotavirus vaccine on diarrhea incidence and mortality using the guidelines established by the Child Health Epidemiology Reference Group (CHERG) [3, 9]. In brief, we conducted a literature search to indentify all Phase III rotavirus vaccine trials of marketed products as of January 2009. We reviewed more than 400 titles and abstracts, screened 17 full papers and included 5 papers in our final review. Since this review [5–8], 4 studies have been published providing additional data for Asia and sub-Saharan Africa, where previous data were not available.
Countdown to 2015 and GAVI eligible countries by under 5 mortality rate and region for use in applying rotavirus vaccine effect size
< 5 Mortality Rate
< 5 Mortality Rate
Low mortality Asia and North Africa
Sao Tome and Principe
High mortality Asia
Papua new guinea
For outcomes and regions where more than one study had data available, we preformed both fixed and random effect meta-analyses using STATA statistical software. We reported the Mantel-Haenszel pooled relative risk and corresponding 95% confidence interval (CI).
In this review we present the first analysis of all rotavirus vaccine efficacy studies published for the currently recommended rotavirus vaccines with the intent of estimating region specific effect of the rotavirus vaccine on diarrhea mortality. We initially abstracted data on all diarrhea outcomes included in the publications. However, in this analysis we sought to estimate the effect of rotavirus vaccine on diarrhea mortality thus focused on the most severe study outcomes as the best proxy for an anticipated mortality reduction where mortality data are lacking. Studies measured reductions in severe rotavirus disease and rotavirus hospitalizations; we chose a final effect size based on reduction in severe rotavirus incidence as this outcome was measured in all geographic regions and was consistently the more conservative estimate as compared to reductions in rotavirus hospitalizations. Though vaccine trials have not directly measured the effect of vaccine on diarrhea mortality, two recent studies in Brazil and Mexico have shown marked reductions in diarrhea mortality in communities that achieved high rates of rotavirus vaccination [15, 16]. For these reasons, we believe the overall quality of the evidence and consistency observed across studies suggests that estimating mortality based on a severe morbidity reduction is highly plausible.
Vaccine trials to date have been focused on severe diarrhea and thus have not included outcome measures to capture the effect of vaccine on diarrhea incidence of any severity. For this reason the LiST model does not include the effect of rotavirus vaccine on diarrhea incidence. Though it is expected that the rotavirus vaccine would have a small effect on all cause diarrhea incidence, there are no data to suggest the size of this effect . Because the effect of vaccine on mortality is captured here, the small additional benefit via the diarrhea incidence pathway would be negligible in the model.
In this analysis we only included studies that assessed efficacy or effectiveness among fully vaccinated children. In our previous review we included two case control studies that categorized a child as vaccinated if he/she had received only 1 dose of vaccine [18, 19]. The goal of LiST is to provide accurate estimates of an anticipated effect of an intervention on cause-specific mortality at a given coverage point. Because rotavirus vaccine coverage indicators are designed to measure the proportion of children who received the full vaccine dose, we estimated the effect size here including only fully vaccinated children to ensure consistency. We have not attempted to capture any additional effect the vaccine may have with regard to population level herd immunity; studies to date have not been designed to capture this and thus a possible effect is impossible to quantify.
There are numerous hypotheses as to why the protective efficacy of the vaccine varies by region and study population with markedly lower protective efficacy rates in populations with high infant mortality. Some reasons may include variation in host response due to passive immunity via breastfeeding or underlying nutritional differences; differences in rates of severe disease; and variation in endemic disease versus seasonal peaks. It is also possible that bacteria and other viruses may remain important causes of severe morbidity in low-income settings as compared to children in high-income settings where improvements in water and sanitation have virtually eliminated these pathogens from the community setting. Co-infection with more than one potential pathogen in these settings is common and it is possible that the rotavirus found by sensitive assays in the stool is not always the organism causing the illness. The frequent encounter with fecal pathogens may also lead to “environmental enterpathy” which, while protecting the child to some degree from falling repeatedly ill due to routine pathogens, this may also create a hostile environment for eliciting a lower immune response to the vaccine . There is also limited evidence to suggest that substantial variation in strains included in the vaccine and subsequent circulating stains in the community may cause lower effectiveness in the community, quantifying the effect of this variation across settings is difficult . Unfortunately, the appropriate studies have not been done to determine which, if any, of these hypotheses explains the observed differences. Additional descriptive etiology studies are needed to more fully understand the role of various pathogens; including differences in rotavirus strains in causing severe disease in developing countries and the relative pathogenicity, i.e. the likelihood of individual pathogens to cause disease. Understanding why protective efficacy varies by population is critical to improve upon the currently available vaccine or to enhance the individual effect of the vaccine within different populations.
Despite the reduced effect size observed in low-income populations, the rotavirus vaccine may still reduce rotavirus mortality by 50%, an important benefit for some of the world’s most vulnerable children. Rotavirus vaccine can be delivered on the routine immunization schedule providing an opportunity to prevent morbidity and mortality in areas where care seeking behaviors for diarrhea are not ideal. Preventing diarrhea mortality needs a multi-prong approach. We have numerous preventive and treatment tools, including rotavirus vaccine and oral rehydration and zinc for management of illness. Countries and international organizations need to prioritize control of diarrheal mortality as part of a comprehensive child survival strategy.
There is strong evidence suggesting that rotavirus vaccine decreases rotavirus specific mortality and thus all diarrhea mortality in all regions of the world. Though the effect size appears to be greater among children living in developed countries as compared to low-income countries, the increased risk of diarrhea mortality is greater in developing countries therefore increasing the justification for the continued promotion of this important child survival tool.
The authors thank Laura Lamberti for her assistance with the figures and Loni Ajagbe for her assistance with data abstraction and figures. The study was supported by a grant from the Bill and Melinda Gates Foundation to the US Fund for UNICEF for the ongoing work of the Child Health Epidemiology Reference Group.
This article has been published as part of BMC Public Health Volume 11 Supplement 3, 2011: Technical inputs, enhancements and applications of the Lives Saved Tool (LiST). The full contents of the supplement are available online at http://www.biomedcentral.com/1471-2458/11?issue=S3.
- Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, et al: Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010, 375 (9730): 1969-1987. 10.1016/S0140-6736(10)60549-1.View ArticlePubMedGoogle Scholar
- Parashar UD, Gibson CJ, Bresse JS, Glass RI: Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006, 12 (2): 304-306. 10.3201/eid1202.050006.PubMed CentralView ArticlePubMedGoogle Scholar
- Munos MK, Walker CL, Black RE: The effect of rotavirus vaccine on diarrhoea mortality. Int J Epidemiol. 2010, 39 (Suppl 1): i56-62. 10.1093/ije/dyq022.PubMed CentralView ArticlePubMedGoogle Scholar
- Soares-Weiser K, Goldberg E, Tamimi G, Pitan OC, Leibovici L: Rotavirus vaccine for preventing diarrhoea. Cochrane Database Syst Rev. 2004, CD002848-1
- Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al: Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010, 362 (4): 289-298. 10.1056/NEJMoa0904797.View ArticlePubMedGoogle Scholar
- Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, et al: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010, 376 (9741): 606-614. 10.1016/S0140-6736(10)60889-6.View ArticlePubMedGoogle Scholar
- Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, et al: Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010, 376 (9741): 615-623. 10.1016/S0140-6736(10)60755-6.View ArticlePubMedGoogle Scholar
- Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, et al: Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine. 2009, 27 (43): 5936-5941. 10.1016/j.vaccine.2009.07.098.View ArticlePubMedGoogle Scholar
- Walker N, Fischer-Walker C, Bryce J, Bahl R, Cousens S: Standards for CHERG reviews of intervention effects on child survival. Int J Epidemiol. 2010, 39 (Suppl 1): i21-31. 10.1093/ije/dyq036.PubMed CentralView ArticlePubMedGoogle Scholar
- Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, et al: Grading quality of evidence and strength of recommendations. BMJ. 2004, 328 (7454): 1490-10.1136/bmj.328.7454.1490.View ArticlePubMedGoogle Scholar
- de Palma O, Cruz L, Ramos H, de Baires A, Villatoro N, Pastor D, de Oliveira LH, Kerin T, Bowen M, Gentsch J, et al: Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ. 2010, 340: c2825-10.1136/bmj.c2825.PubMed CentralView ArticlePubMedGoogle Scholar
- Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, Lopez P, Macias-Parra M, Ortega-Barria E, Rivera-Medina DM, et al: Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008, 371 (9619): 1181-1189. 10.1016/S0140-6736(08)60524-3.View ArticlePubMedGoogle Scholar
- Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A: Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007, 370 (9601): 1757-1763. 10.1016/S0140-6736(07)61744-9.View ArticlePubMedGoogle Scholar
- Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, et al: Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006, 354 (1): 23-33. 10.1056/NEJMoa052664.View ArticlePubMedGoogle Scholar
- Lanzieri TM, Linhares AC, Costa I, Kolhe DA, Cunha MH, Ortega-Barria E, Colindres RE: Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis. 2010Google Scholar
- Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, Gomez-Altamirano CM, Parashar U, Patel M: Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med. 2010, 362 (6): 299-305. 10.1056/NEJMoa0905211.View ArticlePubMedGoogle Scholar
- Lanata CF, Midthun K, Black RE, Butron B, Huapaya A, Penny ME, Ventura G, Gil A, Jett-Goheen M, Davidson BL: Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis. 1996, 174 (2): 268-275. 10.1093/infdis/174.2.268.View ArticlePubMedGoogle Scholar
- Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, Gonzalez A, Malespin O, Amador JJ, Umana J, et al: Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA. 2009, 301 (21): 2243-2251. 10.1001/jama.2009.756.View ArticlePubMedGoogle Scholar
- Snelling TL, Schultz R, Graham J, Roseby R, Barnes GL, Andrews RM, Carapetis JR: Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin Infect Dis. 2009, 49 (3): 428-431. 10.1086/600395.View ArticlePubMedGoogle Scholar
- Levine MM: Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 2010, 8: 129-10.1186/1741-7007-8-129.PubMed CentralView ArticlePubMedGoogle Scholar
- Correia JB, Patel MM, Nakagomi O, Montenegro FM, Germano EM, Correia NB, Cuevas LE, Parashar UD, Cunliffe NA, Nakagomi T: Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P strains in Brazil. J Infect Dis. 2010, 201 (3): 363-369. 10.1086/649843.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.